Migraine Drug Ubrogepant Tackles Debilitating Early Symptoms

www.scientificamerican.com

Migraine Drug Ubrogepant Tackles Debilitating Early Symptoms

www.scientificamerican.com

paywall@rss.ponder.catMB to Scientific American@rss.ponder.catEnglish · 28 days ago

Results from a phase 3 clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent preheadache fatigue and light sensitivity

From Scientific American via this RSS feed

You must log in or register to comment.

Chat

Scientific American@rss.ponder.cat

scientificamerican@rss.ponder.cat

You are not logged in. However you can subscribe from another Fediverse account, for example Lemmy or Mastodon. To do this, paste the following into the search field of your instance: !scientificamerican@rss.ponder.cat

Community locked: only moderators can create posts. You can still comment on posts.

Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.

Visibility: Public

This community can be federated to other instances and be posted/commented in by their users.

0 users / day
0 users / week
0 users / month
0 users / 6 months
0 local subscribers
114 subscribers
50 Posts
0 Comments
Modlog